CAP® Derived Recombinant C1 Inhibitor Matches Berinert® in Animal Study

Product News   Feb 03, 2015

 
CAP® Derived Recombinant C1 Inhibitor Matches Berinert® in Animal Study
 
 
FURTHER INFORMATION
 
 
 

Related Product News

Alderley Park’s ApconiX Acheives Five-Fold Turnover Boost Via Pharma Sector Demand for Drug Safety Expertise

Product News

Alderley Park-based ApconiX – a nonclinical safety company working with the pharmaceutical sector – has achieved a five-fold sales increase in its second year of trading, far exceeding its predicted annual forecast.

READ MORE

ATCC Develops Novel in vitro Model to Investigate Drug Candidates for Cancer Metastasis

Product News

ATCC have announced the release of an innovative, in vitro model system for a key mechanism of invasion and metastasis in lung cancer.

READ MORE

Lonza Expands Service Offerings for Early Phase Biopharmaceutical Drug Development

Product News

Protein Sequence Variant Analysis de-risks clinical candidates. Site-Specific Conjugation Vectors for GS Xceed® System support expression of second-generation antibody drug conjugates. Developability assessment expanded to include microbial-derived recombinant proteins.

READ MORE

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE